6 курс / Кардиология / СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ

Литература

heart failure: results from the Battlescarred (NT;proBNP;Assist; ed Treatment To Lessen Serial Cardiac Readmissions and Death) trial // J. Am. Coll. Cardiol. – 2009. – Vol. 55 (1). – Р. 53–60.

309.Landmesser U., Spiekermann S., Dikalov S. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine;oxidase and extracellular superoxide dis; mutase // Circulation. – 2002. – Vol. 106, No. 24. – P. 3073–3078.

310.Lanfear D.E. Genetic variation in the natriuretic peptide system and heart failure // Heart Fail. Rev. – 2010. – Vol. 15 (3). – Р. 219–228.

311.Lanfear D.E., Stolker J.M., Marsh S. et al. Genetic variation in the B;type natiuretic peptide pathway affects BNP levels // Car; diovasc. Drugs Ther. – 2007. – Vol. 21 (1). – Р. 55–62.

312.Lee Y., Gustafsson A.B. Role of apoptosis in cardiovascular dis; ease // Apoptosis. – 2009. – Vol. 14 (4). – Р. 536–548.

313.Leopold J.A., Loscalzo J. Oxidative enzymopathies and vascular disease // Arterioscler. Thromb. Vasc. Biol. – 2005. – Vol. 25, No. 7. – Р. 1332–1340.

314.Lerman O.Z., Galiano R.D., Armour M. et al. Cellular dysfunction in the diabetic fibroblast: Impairment in migration, VEGF produc; tion and response to hypoxia // Am. J. Pathol. – 2003. – Vol. 162

(1). – Р. 303–312.

315.Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides // N. Eng. J. Med. – 1998. – Vol. 339. – Р. 321–328.

316.Levine B., Kalman J., Mayer L. et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure // N. Engl. J. Med. – 1990. – Vol. 323. – Р. 236–241.

317.Levonen A., Vahakangas E., Koponen J.K. et al. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives // Circulation. – 2008. – Vol. 117 (16). – Р. 2142– 2150.

318.Li J., Schwimmbeck P.L., Tschope C. et al. Collagen degradation in a murine myocarditis model: relevance of matrix metallopro; teinase in association with inflammatory induction // Cardiovasc.

379

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

Res. – 2002. – Vol. 56 (2). – P. 235–247.

319.Li Y., Takemura G., Kosai K. et al. Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure // Circ. Res. – 2004. – Vol. 95 (6). – Р. 627–636.

320.Libe L., Hausdorff J.M., Knight E. Neutrophilia and congestive heart failure after acute myocardial infarction // Am Heart J. – 2000. – Vol. 139. – P. 94–100.

321.Libetta C., Sepe V., Zucchi M. et al. Intermittent haemodiafiltra; tion in refractory congestive heart failure: BNP and balance of inflammatory cytokines // Nephrol. Dial. Transplant. – 2007. – Vol. 22. – P. 1013–2019.

322.Lieb W., Safa R., Benjamin E.J. et al. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clini; cal and genetic correlates and association with vascular func; tion // Eur. Heart J. – 2009. – Vol. 30. – P. 1121–1127.

323.Lin T.H., Su H.M., Wang C.L. et al. Vascular endothelial growth factor polymorphisms and extent of coronary atherosclerosis in Chinese population with advanced coronary artery disease // Am. J. Hypertens. – 2010. – Vol. 23 (9). – Р. 960–966.

324.Lin T.H., Wang C.L., Su H.M. et al. Functional vascular endothe; lial growth factor gene polymorphisms and diabetes: effect on coronary collaterals in patients with significant coronary artery disease // Clin. Chim. Acta. – 2010. – Vol. 411 (21;22). – Р. 1688– 1693.

325.Listeberger L.L., Ory D.S., Schaffer J.A. Palmitate;induced apo; ptosis can occur through a ceramide;independent pathway // J. Biol. Chem. – 2001. – Vol. 276. – P. 14890–14895.

326.Liu L., Eisen H.J. Epidemiology of heart failure and scope of the problem // Cardiol. Clin. – 2014. – Vol. 32 (1). – P. 1–8.

327.Liu P.Y., Li Y.H., Tsai W.C. et al. Stromelysin;1 promoter 5A/6A polymorphism is an independent genetic prognostic risk factor and interacts with smoking cessation after index premature my; ocardial infarction // J. Thromb. Haemost. – 2005. – Vol. 3 (9). – Р. 1998–2005.

380

Литература

328.Lockshin R.A., Zakeri Z. Caspase;independent cell deaths // Curr. Opin. Cell Biol. – 2002. – Vol. 14. – P. 727–733.

329.Logue S.E., Gustafsson A.B., Samali A. et al. Ischemia/reperfu; sion injury at the intersection with cell death // J. Mol. Cell. Car; diol. – 2005. – Vol. 38. – P. 21–33.

330.Lotze U., Heinke S., Fritzenwanger M. et al. Carvedilol inhibits platelet;derived growth factor;induced signal transduction in human cardiac fibroblasts // J. Cardiovasc. Pharmacol. – 2002.

–Vol. 39 (4). – Р. 576–89.

331.Luster T.F., Barton M. Endothelins and endothelin receptor an; tagonists: therapeuttic considerations for a novel class of car; diovascular drugs // Circulation. – 2000. – Vol. 102. – P. 2434– 2440.

332.Ly H., Kawase Y., Yoneyama R., Hajjar R.J. Gene therapy in the treatment of heart failure // Physiology. – 2007. – Vol. 22. – P. 81–96.

333.Ma S., Zhang H., Sun W. et al. Hyperhomocysteinemia induces cardiac injury by up;regulation of p53;dependent Noxa and Bax expression through the p53 DNA methylation in ApoE(;/;) mice // Acta Biochim. Biophys. Sin. (Shanghai). – 2013. – Vol. 45 (5).

–Р. 391–400.

334.MacCord J.M., Roy R.S. The pathophysiology of superoxide: roles in inflammation and ischemia // Can. J. Physiol. Pharmacol. – 1982 – Vol. 60 (11). – Р. 1346–1352.

335.Maisel A.S., Clopton P., Krishnaswamy P. et al. Impact of age, race, and sex on the ability of B;type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breath; ing Not Properly (BNP) multinational study // Am. Heart J. – 2004.

–Vol. 147 (6). – Р. 1078–1084.

336.Malhotra R., Brosius III F.C. Glucose uptake and glycolises re; duce hypoxia;induced apoptosis in cultured neonatal rat cardiac myocytes // J. Biol. Chem. – 1999. – Vol. 274. – Р. 12567–12575.

337.Mallat Z., Tedgui A., Fontaliran F. et al. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia // N. Engl. J. Med. –

381

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

1996. – Vol. 335. – P. 1190–1196.

338.Manginas A., Tsiavou A., Chaidaroglou A. et al. Inflammatory cy; tokine gene variants in coronary artery disease patients in Greece // Coronary Artery Disease. – 2008. – Vol. 19, No. 8. – Р. 575– 582.

339.Marklund S.L. Analysis of extracellular superoxide dismutase in tissue homogenates and extracellular fluids // Methods Enzymol.

– 1990. – Vol. 186. – P. 260–265.

340.Martin R.C.G., Li Y., Liu Q. et al. Manganese superoxide dismu; tase V16A single;nucleotide polymorphism in the mitochondrial targeting sequence is associated with reduced enzymatic activ; ity in cryopreserved human hepatocytes // DNA and Cell Biolo; gy. – 2009. – Vol. 28. – Р. 3–7.

341.Matsumura S., Iwanaga S., Mochizuki S. et al. Targeted deletion or pharmacological inhibition of MMP;2 prevents cardiac rup; ture after myocardial infarction in mice // Clin. Invest. – 2005. – Vol. 115 (3). – P. 599–609.

342.Matute;Bello G., Wurfel M.M., Lee J.S. et al. Essential role of MMP;12 in Fas;induced lung fibrosis // Cell. Mol. Biol. – 2007. – Vol. 37 (2). – Р. 210–221.

343.Maulik N., Goswami S., Galang N. et al. Differential regulation of Bcl;2, AP;1 and NK;kappa B on cardiomyocyte apoptosis dur; ing myocardial ischemic stress adaptation // FEBS Lett. – 1999.

– Vol. 443. – P. 331–336.

344.McIntyre M., Bohr D.F., Dominiczak A.F. Endothelial function in hypertension: the role of superoxide anion // Hypertension. – 1999. – Vol. 34, No. 4. – Р. 539–545.

345.McKie P.M., Rodeheffer R.J., Cataliotti A. et al. Amino;terminal Pro;B;type natriuretic peptide and B;type natriuretic peptide. Biomarkers for mortality in a large community;based cohort free of heart failure // Hypertension. – 2006. – Vol. 47 (5). – Р. 874– 880.

346.Medley T.L., Kingwell B.A., Gatzka C.D. еt al. Matrix metallopro; teinase;3 genotype contributes to age;related aortic stiffening

382

Литература

through modulation of gene and protein expression // Circ. Res.

–2003. – Vol. 92 (11). – P. 1254–1261.

347.Meirhaeghe A., Sandhu M.S., McCarthy M.I. et al. Association between the T;381C polymorphism of the brain natriuretic pep; tide gene and risk of type 2 diabetes in human populations // Hum. Mol. Genet. – 2007. – Vol. 16 (11). – Р. 1343–1350.

348.Michalovitz D., Halevy O., Oren M. Conditional inhibition of trans; formation and of cell proliferation by a temperature;sensitive mutant of p53 // Cell. – 1990. – Vol. 62. – Р. 671–680.

349.Miller D.P., Neuberg D., de Vivo I. et al. Smoking and the risk of lung cancer: susceptibility with GSTP1 polymorphisms // Epide; miology. – 2003. – Vol. 14 (5). – P. 545–551.

350.Moorjani N., Catarino P., Trabzuni D. et al. Upregulation of Bcl;2 proteins during the transition to pressure overloadinduced heart failure // International Journal of Cardiology. – 2007. – Vol. 116

(1). – Р. 27–33.

351.Moscow J.A., Townsend A.J., Goldsmith M.E. et al. Isolation of the human anionic glutathione S;transferase cDNA and the rela; tion of its gene expression to estrogen;receptor content in pri; mary breast cancer // Proc. Nat. Acad Sci. – 1988. – Vol. 85. – Р. 6518–6522.

352.Mughal W., Dhingra R., Kirshenbaum L.A. Striking a balance: autophagy, apoptosis, and necrosis in a normal and failing heart // Curr. Hypertens. Rep. – 2012. – Vol. 14 (6). – P. 540–547.

353.Mukherjee R., Brinsa T.A., Dowdy K.B. et al. Myocardial infarct expansion and matrix metalloproteinase inhibition // Circulation.

–2003. – Vol. 107 (4). – P. 618–625.

354.Mukoyama M., Nakao K., Hosoda K. et al. Brain natriuretic pep; tide as a novel cardiac hormone in humans. Evidence for an ex; quisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide // J. Clin. Invest. – 1991. – Vol. 87.

–Р. 1402–1412.

355.Muller F.L., Lustgarten M.S., Jang Y. et al. Trends in oxidative aging theories // Free Radic. Biol. Med. – 2007. – Vol. 43, No. 4.

383

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

–Р. 477–503.

356.Muller;Werdan U., Werdan K. Immune modulation by catechola; mines – a potential mechanism of cytokine release in heart fail; ure? // Herz. – 2000. – Vol. 25 (3). – P. 271–273.

357.Munter K., Kirchengast M. The role of endothelin receptor an; tagonists in cardiovascular pharmacotherapy // Expert Opin. Emerg. Drugs. – 2001. – Vol. 6. – P. 3–11.

358.Nabel E. Cardiovascular disease // N. Engl. J. Med. – 2003. – Vol. 349, No. 1. – P. 60–72.

359.Nagase H. Activation mechanisms of matrix metalloproteinases // Biol. Chem. – 1997. – Vol. 378 (3–4). – P. 151–160.

360.Nakagawa T., Yuan J. Cross;talk between two cysteine protease families. Activation of caspase;12 by calpain in apoptosis // J. Cell. Biol. – 2000. – Vol. 150. – P. 887;894.

361.Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53 // Mol. Cell. – 2001. – Vol. 7. – Р. 683–694.

362.Namiki A., Brogi E., Kearney M. et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells // J. Biol. Chem. – 1995. – Vol. 270. – P. 31189–31905.

363.Nemoto M., Nishimura R., Sasaki T. et al. Genetic association of glutathione peroxidase;1 with coronary artery calcification in type 2 diabetes: a case control Study with multi;slice computed to; mography // Cardiovasc. Diabetol. – 2007. – Vol. 6. – Р. 23–27.

364.Newton;Cheh C., Larson MG., Vasan R.S. et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure // Nat. Genet. – 2009. – Vol. 41 (3).

–Р. 348–353.

365.Nie Y., Gu H., Gong J. et al. Methylenetetrahydrofolate reduc; tase C677T polymorphism and congenital heart disease: a meta; analysis // Clin. Chem. Lab. Med. – 2011. – Vol. 49 (12). – Р. 2101–2108.

366.Niu J., Kolattukudy P.E. Role of MCP;1 in cardiovascular disease: molecular mechanisms and clinical implications // Clin. Sci.

384

Литература

(Lond). – 2009. – Vol. 117. – Р. 95–109.

367.Nkeh B., Tiago A., Candy G.P. et al. Association between an atri; al natriuretic peptide gene polymorphism and normal blood pres; sure in subjects of African ancestry // Cardiovasc J. S. Afr. – 2002.

–Vol. 13 (3). – Vol. 97–101.

368.Nozik;Grayck E., Suliman H.B., Piantadosi C.A. Extracellular su; peroxide dismutase // Int. J. Biochem. Cell Biol. – 2005. – Vol. 37, No. 12. – Р. 2466–2471.

369.O’Connor D.S., Schechner J.S., Adida C. et al. Control of apop; tosis during angiogenesis by survivin expression in endothelial cells // Amer. J. Pathol. – 2000. – Vol. 156. – Р. 393–398.

370.O’Donoghue M., Chen A., Baggish A.L. et al. The effects of ejec; tion fraction on N;terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dysp; nea in the Emergency Department (PRIDE) Study // J. Card. Fail.

–2005. – Vol. 11 (Suppl. 5). – Р. 9–14.

371.Ohtsuka T., Hamada M., Sasaki O. et al. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute my; ocardial infarction // Coron. Artery Dis. – 1999. – Vol. 10. – P. 221–225.

372.Okubo S., Tanabe Y., Takeda K. et al. Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction af; ter ischemiareperfusion in rabbits: role of delta;opioid receptor // Am. J. Physiol. Heart Circ. Physiol. – 2004. – Vol. 287. – P. H1786–H1791.

373.Okuyan E., Uslu A., Cakar M.A. et al. Homocysteine levels in pa; tients with heart failure with preserved ejection fraction // Cardi; ology. – 2010. – Vol. 117. – Р. 21–27.

374.Olivetti G., Abbi R., Quaini F. et al. Apoptosis in failling human heart // N. Engl. J. Med. – 1997. – Vol. 336. – Р. 1131–1141.

375.Omland T. B;type natriuretic peptides: Prognostic markers in sta; ble coronary artery disease // Expert Rev. Mol. Diagn. – 2008. – Vol. 8 (2). – Р. 217–225.

376.Oral N., Kapadia S., Nakano M. et al. Tumor necrosis factor alfa

385

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

and falling human heart // Clin. Cardiology. – 1995. – Vol. 18 (Sup; pl. IV). – Р. 20–27.

377.Owan Т.Е., Hodge D.О., Herges R.M. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction //

N.Engl. J. Med. – 2006. – Vol. 355. – Р. 251–259.

378.Packer M., Poole;Wilson P., Armstrong P. et al. Comparative ef; fects of low;dose versus high;dose lisinopril on survival and ma; jor events in chronic heart failure: the Assessement of Treatment with Lisinopril And Survival (ATLAS) // Europ. Heart J. – 1998. – Vol. 19. – Р. 142.

379.Palojoki E., Saraste A., Eriksson A. et al. Cardiomyocyte apopto; sis and ventricular remodeling after myocardial infarction in rats // Am. J. Physiol. – 2001. – Vol. 280. – P. H2726–H2730.

380.Parmley W.W. Surviving heart failure: Robert L. Frye lecture // Mayo. Clin. Proc. – 2000. – Vol. 75. – P. 111–118.

381.Patti G., Fossati C., Nusca A. et al. Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late inf; arct;related coronary artery patency after thrombolysis // J. Thromb. Thrombolysis. – 2009. – Vol. 27 (4). – Р. 413–420.

382.Paulus W.J. How are cytokines activated in heart failure? // Eur.

J.Heart Fail. – 1999. – Vol. 1 (4). – P. 309–312.

383.Pelliccia A., Thompson P.D. The genetics of left ventricular re; modeling in competitive athletes // J. Cardiovasc. Med. – 2006.

– Vol. 7. – Р. 267–270.

384.Perianayagam M. C., Liangos O., Kolyada A. Y. et al. NADPH Ox; idase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure // J. Am. Soc. Nephrol. – 2007. – Vol. 18, No.1. – Р. 255–263.

385.Petrovic D., Verhovec R., Globocnik Petrovic M. et al. Associa; tion of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes // Cardiol; ogy. – 2007. – Vol. 107 (4). – Р. 291–295.

386.Pickett C.B., Lu A.Y. Glutathione S;transferases: gene structure,

386

Литература

regulation, and biological function // Annu. Rev. Biochem. – 1989.

–Vol. 58. – Р. 743–764.

387.Pilbrow A.P., Palmer B.R., Frampton C.M. et al. Angiotensinogen M235 T and T174M gene polymorphisms in combination dou; bles the risk of mortality in heart failure // Hypertension. – 2007.

–Vol. 49. – P. 322–327.

388.Pim D., Banks L. P53 polymorphic variants at codon 72 exert dif; ferent effects on cell cycle progression // Int. J. Cancer. – 2004.

–Vol. 108. – P. 196–199.

389.Pinto X., Vilaseca M.A., Garcia;Giralt N. et al. Homocysteine Study Group Homocysteine and the MTHFR 677C;T allele in prema; ture coronary artery disease. Case control and family studies // Eur. J. Clin. Invest. – 2001. – Vol. 31. – P. 24–30.

390.Plischke M., Neuhold S., Adlbrecht C. et al. Inorganic phosphate and FGF;23 predict outcome in stable systolic heart failure // Eur. J. Clin. Invest. – 2012. – Vol. 42 (6). – Р. 649–656.

391.Poling J., Gajawada P., Richter M. et al. Therapeutic targeting of the oncostatin M receptor;в prevents inflammatory heart failure // Basic Res Cardiol. – 2014. – Vol. 109 (1). – P. 396.

392.Poreba R., Poczatek K., Gaс P. et al. SNP rs198389 (T;381 C) polymorphism in the B;type natriuretic peptide gene promoter in patients with atherosclerotic renovascular hypertension // Pol. Arch. Med. Wewn. – 2009. – Vol. 119 (4). – P. 219–224.

393.Priori S. Inherited arrhythmogenic diseases. The complexity be; yond monogenic disorders // Circ. Res. – 2004. – Vol. 94 (2). – Р. 140–145.

394.Rahman T., Baker M., Hall D.H. et al. Common genetic variation in the type A endothelin;1 receptor is associated with ambulato; ry blood pressure: a family study // J. Hum. Hypertens. – 2008. – Vol. 22 (4). – Р. 282–288.

395.Rahmutula D., Nakayama T., Soma M. et al. Systematic screen; ing of type B human natriuretic peptide receptor gene polymor; phisms and association with essential hypertension // J. Hum. Hypertens. – 2001. – Vol. 15 (7). – Р. 471–474.

387

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

396.Ran Q., Liang H., Ikeno Y. et al. Reduction in glutathione peroxi; dase 4 increases life span through increased sensitivity to apop; tosis // J. Gerontol. Biol. Sci. Med. Sci. – 2007. – Vol. 62, No. 9.

– Р. 932–942.

397.Reeve J.L., Duffy A.M., O’Brien T. et al. Don’t lose heart – thera; peutic value of apoptosis prevention in the treatment of cardio; vascular disease // J. Cell Mol. Med. – 2005. – Vol. 9 (3). – P. 609–622.

398.Ricci C., Pastukh V., Schaffer S.W. Involvement of the mitochon; drial permeability transition pore in angiotensin II mediated apo; ptosis // Exper. Clin. Cardiology. – 2005. – Vol. 10 (3). – Р. 160– 164.

399.Rivera M., Cortes R., Portoles M. et al. Plasma concentration of big endothelin;1 and its relation with plasma NT;proBNP and ventricular function in heart failure patients // Rev. Esp. Cardiol; ogy. – 2005. – Vol. l58. – P. 241–243.

400.Rodriguer M., Lucchesi B.R., Schaper J. Apoptosis in myocar; dial infarction // Ann. Med. – 2002. – Vol. 34. – P. 470–479.

401.Rodriguez;Vita J., Ruiz;Ortega M., Ruperez M. et al. Endothe; lin;1, via ETA receptor and independently of transforming growth factor;beta, increases the connective tissue growth factor in vas; cular smooth muscle cells // Circ. Res. – 2005. – Vol. 23. – P. 14–19.

402.Rolande D.M., Fantini J.P., Cardinalli Neto A. et al. Prognostic determinants of patients with chronic systolic heart failure sec; ondary to systemic arterial hypertension // Arq. Bras. Cardiol. – 2012. – Vol. 98 (1). – P. 76–84.

403.Rothermund L., Pinto Y.M., Hocher B. et al. Cardiac endothelin system impairs left ventricular function in rennin;dependent hy; pertension via sarcoplasmic reticulum Ca 2+ uptake // Circula; tion. – 2000. – Vol. 102. – P. 1582–1588.

404.Rudofsky G., Schlotterer A., Reismann P. et al. The –174G/C IL; 6 gene promoter polymorphism and diabetic microvascular com; plications // Horm. Metab. Res. – 2009. – Vol. 41, No. 4. – P. 308–313.

388